Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease.

Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease.
复制标题

DOI:
10.1021/cn100109k
复制
发表时间:
2011-04-20
影响因子:
5
通讯作者:
LoGrasso, Philip
LoGrasso, Philip
中科院分区:
医学3区
文献类型:
--
作者:
Chambers, Jeremy W.;Pachori, Alok;Howard, Shannon;Ganno, Michelle;Hansen, Donald, Jr.;Kamenecka, Ted;Song, Xinyi;Duckett, Derek;Chen, Weimin;Ling, Yuan Yuan;Cherry, Lisa;Cameron, Michael D.;Lin, Li;Ruiz, Claudia H.;LoGrasso, Philip

文献摘要

参考文献

被引文献

相似文献

目前还没有治疗帕金森病(PD)神经退行性变的药物,现有的所有药物都只能治疗症状,随着时间的推移会失去疗效,并产生不良的副作用。在目前的工作中,我们报道了第一个高选择性,口服生物可利用的c-jun- n末端激酶(JNK)抑制剂,用于体外和体内保护多巴胺能神经元。在300 nM时,该化合物对暴露于1-甲基-4-苯基吡啶(MPP+)的初级多巴胺能神经元具有统计学显著的保护作用,在啮齿动物中具有与每日两次(b.i.d)剂量一致的药代动力学特性,并且在小鼠1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)帕金森病模型中以30 mg/kg的剂量口服有效。此外,c-jun磷酸化的剂量依赖性靶标调节作为一种生物标志物,证明了该化合物对JNK的靶向抑制是其作用机制。总之,这些结果表明,这种JNK抑制剂可能是治疗帕金森病的一种有前途的治疗性神经保护剂。
There are currently no drugs to treat neurodegeneration in Parkinson’s disease (PD) and all existing medications only treat symptoms, lose efficacy over time, and produce untoward side effects. In the current work, we report the first highly selective, orally bioavailable, c-jun-N-terminal kinase (JNK) inhibitor for protection of dopaminergic neurons in vitro and in vivo. At 300 nM this compound showed statistically significant protection of primary dopaminergic neurons exposed to 1-methyl-4-phenylpyridinium (MPP+), had pharmacokinetic properties in rodents consistent with twice daily (b.i.d.) dosing, and was orally efficacious at 30 mg/kg in a mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson’s disease. Moreover, a dose-dependent target modulation of c-jun phosphorylation served as a biomarker for demonstrating on-target inhibition of JNK as the mechanism of action for this compound. Collectively these results suggest that this JNK inhibitor could be a promising therapeutic neuroprotective agent in the treatment of Parkinson’s disease.
DOI: 10.1038/nn.2349
发表时间: 2009-07
影响因子: 25
作者:
Li, Yanping;Liu, Wencheng;Oo, Tinmarla F.;Wang, Lei;Tang, Yi;Jackson-Lewis, Vernice;Zhou, Chun;Geghman, Kindiya;Bogdanov, Mikhail;Przedborski, Serge;Beal, M. Flint;Burke, Robert E.;Li, Chenjian
通讯作者: Li, Chenjian
DOI: 10.1038/nprot.2006.342
发表时间: 2007-01-01
期刊: NATURE PROTOCOLS
影响因子: 14.8
作者:
Jackson-Lewis, Vernice;Przedborski, Serge
通讯作者: Przedborski, Serge
DOI: 10.1111/j.1471-4159.2005.03329.x
发表时间: 2005-09-01
影响因子: 4.7
作者:
Chu, CT;Zhu, J;Chen, J
通讯作者: Chen, J
DOI: 10.1523/jneurosci.22-05-01763.2002
发表时间: 2002-03-01
影响因子: 5.3
作者:
Wu, DC;Jackson-Lewis, V;Przedborski, S
通讯作者: Przedborski, S
DOI: 10.1111/j.1471-4159.2005.03253.x
发表时间: 2005-08-01
影响因子: 4.7
作者:
Cleren, C;Calingasan, NY;Beal, MF
通讯作者: Beal, MF